maxproventures.comCrawled Oct 27, 2026
With its ongoing Phase 1 clinical trial of ACE1702 for the treatment of HER2-expressing solid tumors, Acepodia hopes to make a case for fast, affordable, and effective off-the-shelf cell therapies.
The company developed a novel human NK cell line, oNK-1, which expresses CD16 and high levels of NK activation markers.
When our backs were against the wall, the biotech/biopharma community came together to create not one, but two vaccines currently approved for emergency use in the U.S. This has earned the industry a lot of respect. The lessons learned from the global pandemic are expected to translate to existing and emerging therapeutic areas - particularly oncology; more efficient regulatory-industry relationships; mRNA is a word we will continue to hear a lot about; and home health care is here to stay. Thes
Advaxis, Inc. completed agreements with two institutional investors to purchase 17,577,400 shares of common stock, 7,671,937 pre-funded warrants, and registered warrants for 11,244,135 additional shares.
The Phase 2 SUMMIT study evaluated neratinib in patients with EGFR exon 18 or ERBB2 mutations, showing efficacy in lung cancer patients with prior EGFR TKI treatment.
SyneuRx presented research at the 2021 Joint Spring Congress, showing that its omega form of sodium benzoate improves solubility, bioavailability, and antipsychotic effects.
ACE2016 Is an Allogeneic Gamma Delta 2 (γδ2) T Cell Therapy Targeting the Epidermal Growth Factor Receptor (EGFR) in Patients With Solid Tumors.
Anbogen Therapeutics completed its Series A funding round, led by China Development Industrial Bank with contributions from Taian Venture Capital, Maxpro, and the National Development Fund.
Anbogen Therapeutics received the 21st National Innovation Award for its lead asset ABT-301, highlighting its potential in cancer immunotherapy for microsatellite-stable colorectal cancer.
Apollomics Inc. appointed Matthew Plunkett, Ph.D., as its Chief Financial Officer.
TAHO Pharmaceuticals reported positive preliminary results for TAH3311, confirming bioequivalence to Apixaban tablets under fasting conditions in a study of 60 healthy volunteers.
Maxpro Ventures invests in biomedical technology companies, leveraging expertise in biomedical, financial, and operational fields.
a leading biomedical venture capital firm
Anbogen Therapeutics raises $12.5 million in Series A funding to accelerate the development of precision oncology drugs. The clinical-stage biotech company focuses on innovative cancer treatments. Investors back its pipeline of targeted therapies designed to improve patient outcomes.
MCA becomes Taiwan’s first SPAC to list on Nasdaq, enabling unlisted companies to pursue U.S. IPOs via special purpose acquisition vehicles. The initiative targets Taiwanese firms seeking alternative public market access amid rising IPO activity in late 2021. The team’s identity remains undisclosed, though their formation aligns with a broader regional trend of SPAC filings.
Maxpro Capital Acquisition, a Taiwan-based SPAC led by Maxpro Ventures, completes a $90 million IPO by issuing 9 million units at $10 each. Each unit includes one share and a warrant exercisable at $11.50, focusing on acquisitions in healthcare and technology sectors. The SPAC aims to deploy capital toward merging with an operating company in its target industries.